Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website.

Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active.
Coronavirus disease 2019 re-infection: first report from Turkey

R. Ozaras1), I. Ozdogru2) and A. A. Yilmaz3)
1) Infectious Diseases Department, 2) Cardiology Department and 3) Surgery Department, Medilife Health Group, Istanbul, Turkey

Abstract

There are concerns about the possibility of SARS-CoV-2 re-infection and recently, a patient with SARS-CoV-2 re-infection (or COVID-19) confirmed by epidemiological, clinical, serological and genomic analyses have been published. We have noticed another patient with SARS-CoV-2 re-infection based on clinical and laboratory studies: A 23-year-old woman presented to her hospital with fever (39°C), chills, fatigue, cough, headache, sore throat, muscle and joint pain on April 9, 2020. On examination, oropharynx was mildly hyperemic, and chest auscultation was normal. SARS-CoV-2 PCR from nasopharyngeal specimen was ordered. She was given isotonic saline and acetaminophen, and prescribed azithromycin and acetaminophen and sent home for isolation. SARS-CoV-2 PCR was reported positive and she was given hydroxychloroquine for five days. She improved in 10 days and PCR studies on April 22 and April 27 remained negative. On 4 August 2020, she was re-admitted with fever (38.7°C), chills, fatigue, loss of appetite, taste and smell loss, muscle and joint pain. On examination, oropharynx and chest auscultation were normal. SARS-CoV-2 PCR was reported positive and she was prescribed hydroxychloroquine for five days. She improved in 10 days and PCR studies on 22 April and 27 April remained negative. She did not work for 2 months; and began to work in July 2020.

On 4 August 2020, she was re-admitted with fever, chills, fatigue, loss of appetite, taste and smell loss, muscle and joint pain (39°C), and oropharynx was mildly hyperemic, and chest auscultation was normal. Laboratory studies showed that haemoglobin was 12.8 g/dL; white cells were 8.8 × 10⁹/L; neutrophils were 6.3 × 10⁹/L; lymphocytes were 1.9 × 10⁹/L and C-reactive protein concentration was normal. A chest CT remained negative.

SARS-CoV-2 PCR from a nasopharyngeal specimen was ordered. She was given isotonic saline and acetaminophen; she then prescribed azithromycin and acetaminophen and sent home for isolation. SARS-CoV-2 PCR (with a Ct value of 38) was reported positive and she was given hydroxychloroquine, 200 mg bid for 5 days. She improved in 10 days and PCR studies on 22 April and 27 April remained negative. She did not work for 2 months; and began to work in July 2020.

© 2020 The Author(s). Published by Elsevier Ltd.

Keywords: Antibody, coronavirus, COVID-19, immunity, re-infection

Original Submission: 5 September 2020; Revised Submission: 25 September 2020; Accepted: 29 September 2020

Article published online: 3 October 2020

Corresponding author: R. Ozaras, Infectious Diseases Department, Medilife Hospital, TR-34524 Beylikduzu, Istanbul, Turkey.
E-mail: rozaras@yahoo.com
pain. On examination, she had fever (38.7°C), oropharynx and chest auscultation were normal. Laboratory studies showed haemoglobin 14.6 g/dL; white cells were 6.7 × 10⁹/L; neutrophils were 3.6 × 10⁹/L; lymphocytes were 2.4 × 10⁹/L and C-reactive protein concentration was normal. SARS-CoV-2 PCR (with a Ct value of 38) was reported positive and she was prescribed hydroxychloroquine, acetaminophen and sent home for isolation again. She improved in 1 week (taste/smell loss improved in 10 days) and on a follow-up visit after 14 days, she was doing well. PCR was negative on 17 August 2020. Her anti-SARS-CoV-2 antibodies (IgM + IgG; Roche, Basel, Switzerland) were negative on 17 August 2020 and slightly positive (2.14 signal-to-cutoff) on 29 August 2020 (Fig. 1).

Early laboratory and clinical studies are reassuring against the possibility of re-infection: monkeys re-challenged with the same SARS-CoV-2 strain after recovery from initial infection demonstrate no evidence of recurrent disease [2]. Among the patients who were re-tested as PCR positive after clinical recovery from coronavirus disease 2019 (COVID-19), there were no cases in which complete virus could be isolated in cell culture, suggesting against these patients having been actively infected [3]. To et al. [4] showed that viral genomes from the first and second episodes belonged to different clades/lineages. They described a second episode of asymptomatic infection that occurred 142 day after the first symptomatic episode. Ours is the first report describing two symptomatic episodes 116 days apart.

The drawback of the current report is that there is no genomic analysis; it is not known whether the two episodes were caused by the same clade/lineage. We conclude that as more patients recover from COVID-19, increased awareness may delineate the characteristics of re-infection.

**Conflict of interest**

The authors declare that they have no conflict of interest.

**References**

[1] Osman AA, Al Daajani MM, Alsaha AJ. Re-positive COVID-19 PCR test: could it be a re-infection? New Microb New Infect 2020. https://doi.org/10.1016/j.nmni.2020.100748. Available from:.

[2] Bao L, Deng W, Gao H, Xiao C, Liu J, Xue J, et al. Lack of reinfection in rhesus macaques infected with SARS-CoV-2. BioRxiv 2020 Mar 13:990226. epub ahead of print.

[3] “Findings from investigation and analysis of re-positive cases”. Division of Risk assessment and International cooperation. Updated 21 May 2020. Available from: https://www.cdc.go.kr/board/board.es?mid=a30402000000&bid=0030. [Accessed 24 August 2020].

[4] To KK, Hung IF, Ip JD, Chu AWH, Chan WM, Tam AR, et al. COVID-19 re-infection by a phylogenetically distinct SARS-coronavirus-2 strain confirmed by whole genome sequencing. Clin Infect Dis 2020. ciaa1275. [published online ahead of print, 2020 Aug 25].